Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial by Mitsudomi Tetsuya, Morita Satoshi, Yatabe Yasushi, Negoro Shunichi, Okamoto Isamu, Tsurutani Junji, Seto Takashi, Satouchi Miyako, Tada Hirohito, Hirashima Tomonori, Asami Kazuhiro, Katakami Nobuyuki, Takada Minoru, Yoshioka Hiroshige, Shibata Kazuhiko, Kudoh Shinzoh, Shimizu Eiji, Saito Hiroshi, Toyooka Shinichi, Nakagawa Kazuhiko, Fukuoka Masahiro, West Japan Oncology Group in The lancet oncology (2010). PubMed

Abstract

Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib. However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain.

[ hide abstract ]

Discussed In Paper

Related In Paper

Variant Annotations

Sign in to see variant annotations.